Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy.
J Cardiovasc Transl Res
; 2(2): 182-90, 2009 Jun.
Article
en En
| MEDLINE
| ID: mdl-20559986
ABSTRACT
The purpose of this study was to determine the effects of chronic treatment with the beta 2 adrenergic receptor agonist clenbuterol on endothelial progenitor cells (EPC) in a well-characterized model of heart failure, the muscle LIM protein knockout (MLP(-/-)) mouse. MLP(-/-) mice were treated daily with clenbuterol (2 mg/kg) or saline subcutaneously for 6 weeks. Clenbuterol led to a 30% increase in CD31(+) cells in the bone marrow of MLP(-/-) heart failure mice (p < 0.004). Clenbuterol did not improve ejection fraction. Clenbuterol treatment in MLP(-/-) mice was associated with significant changes in the following circulating factors tissue inhibitor of metalloproteinase-type 1, leukemia inhibitory factor 1, C-reactive protein, apolipoprotein A1, fibroblast growth factor 2, serum glutamic oxaloacetic transaminase, macrophage-derived chemokine, and monocyte chemoattractant protein-3. Clenbuterol treatment in the MLP(-/-) model of heart failure did not rescue heart function, yet did increase CD31(+) cells in the bone marrow. This is the first evidence that a beta 2 agonist increases EPC proliferation in the bone marrow in a preclinical model of heart failure.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Células Madre
/
Biomarcadores
/
Clenbuterol
/
Agonistas Adrenérgicos beta
/
Células Endoteliales
/
Proliferación Celular
/
Agonistas de Receptores Adrenérgicos beta 2
/
Cardiomiopatías
/
Miocardio
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
J Cardiovasc Transl Res
Asunto de la revista:
ANGIOLOGIA
/
CARDIOLOGIA
Año:
2009
Tipo del documento:
Article
País de afiliación:
Estados Unidos